経路と肝臓の出血モデルにおける商用薬の比較分析
Kyle Patterson1,2, Adelle M Dagher1,2, Meredith Lackie1,2
1Battlefield Shock and Organ Support Laboratory, The Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.
PloS one
|August 29, 2025
まとめ
適用経験に関係なく,5つの商用血液静止剤が豚のモデルで交差点および腹腔内出血を効果的に制御しました. すべての薬剤は同様の有効性を示し,再出血率や生存率は有意な差異は見られなかった.
科学分野:
- トラウマと緊急医療
- 手術による血液静止
- 傷の治療
背景:
- 血流は戦闘で 予防可能な死因の1つです
- 長期にわたる脱出の際には,非圧縮性幹と交差点の出血の管理が重要です.
- 局所用 止血剤は 急速な出血制御のための 潜在的な解決策を提供します.
研究 の 目的:
- 5つの商業用局所的血静止剤の有効性を評価する.
- 凝固病の条件下で無制御の出血モデルでの薬剤の性能を評価する.
- 適用器の経験が血液静止剤の効能に与える影響を調べる.
主な方法:
- ランダム化試験では 60 匹のヨークシャー豚を使用した.
- モデルには5センチの股関節動脈切開と6センチの肝臓切開が含まれていた.
- 薬剤は50%の血液希釈後に経験者および未経験者によって投与された.
- 動物は60分間,再出血を観察した.
主要な成果:
- 5つの薬剤 (Combat Gauze,Celox Rapid,ChitoSAM 100,EVARREST® Fibrin Sealant Patch,X- Stat 30) の間で再出血率や生存率が有意な差異は認められなかった.
- ほとんどの薬剤の適用経験は,血静性や再出血率に有意な影響を及ぼさなかった.
- ChitoSAM 100は,交差点出血の制御のために,初心者によってより多くの適用を必要とした.
結論:
- 試験された5つの血液静止剤は,交差点および腹腔内出血の制御において,同様の有効性を示した.
- 適用者の経験は,薬剤の全体的な有効性を変化させなかった.
- この包帯は重症室での 急速な出血制御に 有望です
関連する概念動画
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
01:05Introduction to Hemostasis
8.9K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.9K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
9.2K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.2K